SMALL CELL LUNG CANCER

This study tests a new drug called ABBV-706 combined with the immunotherapy atezolizumab as a first treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. About 180 adults will receive either the new combination at one of two dose…

This study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and …

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This phase 3 trial tests whether adding the drug tarlatamab to standard chemotherapy and immunotherapy helps people with extensive-stage small-cell lung cancer live longer. About 330 participants will be randomly assigned to receive either the new combination or standard treatmen…

This Phase 3 trial tests ZL-1310, a drug that delivers chemotherapy directly to cancer cells, in people with small cell lung cancer that has returned after initial treatment. About 480 participants will receive either ZL-1310 or one of three standard treatments. The study aims to…

This phase 1 trial tests an experimental drug, DXC006, in people with advanced solid tumors (like small cell lung cancer and neuroblastoma) or blood cancers (like multiple myeloma) who have not responded to standard treatments. DXC006 is an antibody-drug conjugate designed to del…

This study tests whether combining two drugs, YL201 and ivonescimab, can safely shrink tumors in people with advanced solid cancers, including lung cancer. About 260 adults whose cancer has not responded to other treatments will receive the combination. The goal is to find the be…

This study tests whether adding focused radiation or ablation to standard drug therapy can help people with lung cancer that has only a few new spots of growth. The goal is to see if this approach allows patients to stay on their current treatment longer without needing to switch…

This study tests whether stereotactic radiosurgery (SRS), a precise form of radiation, can effectively treat brain metastases in people newly diagnosed with small cell lung cancer that has spread to the brain. About 62 participants will receive SRS, and researchers will track how…

This phase 2 trial tests whether adding chest radiotherapy to maintenance immunotherapy (atezolizumab) can better control extensive-stage small cell lung cancer. About 37 adults whose cancer shrank after initial chemo-immunotherapy will receive targeted radiation to the chest alo…

This Phase 2 trial tests the drug alisertib in 120 people with extensive stage small cell lung cancer that has worsened after standard treatments like chemotherapy and immunotherapy. The goal is to see if alisertib can shrink tumors or slow the disease, and to identify which pati…

This study tests a new medicine called PF-08634404 given with chemotherapy for adults with transformed small cell lung cancer (T-SCLC), a rare and aggressive cancer that develops from another lung cancer type. About 40 participants will receive the drug combo through IV infusions…

This study tests a new drug called ifinatamab deruxtecan (I-DXd) against standard treatments for people whose small cell lung cancer has returned. About 540 adults with advanced disease will be randomly assigned to receive either I-DXd or a treatment chosen by their doctor. The g…

This study tests a new drug called ifinatamab deruxtecan in people with advanced solid tumors that have not been cured by other treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 250 participants will take part, and those who benefit may …

This early-phase trial is testing whether combining two experimental drugs, tarlatamab and ZL-1310, with or without the immunotherapy durvalumab, can safely shrink tumors in people with small cell lung cancer that has worsened after standard treatment. About 160 adults will take …

This study tests whether lower doses of chemotherapy can effectively control lung cancer in patients aged 70+ or those with other health problems. About 280 participants will receive pre-set reduced chemo doses to see if tumors shrink while causing fewer side effects. The goal is…

This early-stage trial is testing a new drug called BL-M14D1 in about 120 people with advanced small cell lung cancer or other neuroendocrine cancers that have spread or cannot be removed. The drug works by homing in on a protein called DLL3 found on these cancer cells and delive…

This early-phase study tests an experimental therapy called V001 Injection, which aims to create cancer-fighting cells directly inside the body. It is for people with advanced blood cancers or solid tumors that have not responded to standard treatments. The main goals are to chec…

This study compares two drug combinations for people with extensive-stage small-cell lung cancer who haven't had prior treatment. One group gets teniposide, cisplatin, and serplulimab; the other gets the standard etoposide, cisplatin, and serplulimab. The goal is to see which com…

This Phase 2 trial tests an oral drug called veonetinib (AL8326) in 80 adults with advanced small cell lung cancer, non-small cell lung cancer, or renal cell carcinoma who have already tried at least one prior treatment. The study aims to find the best dose and see if the drug ca…

This study tests a new drug called SKB518 in 192 adults with lung cancer (non-small cell or small cell). The goal is to see if it shrinks tumors and to check for side effects. Participants receive the drug alone until their disease gets worse or side effects become too severe.

This study tests a new drug combination (SKB500) in 80 adults with small cell lung cancer, a fast-growing type of lung cancer. The goal is to see if the treatment is safe and can shrink tumors or slow the disease. Participants must be 18-75 and have extensive-stage cancer, with s…

This study tests a combination of the drug serplulimab plus chemotherapy in people whose lung cancer changed from one type (EGFR-mutated non-small cell) to a more aggressive type (small-cell). About 66 adults aged 18-75 will take part. The goal is to see if the combo can slow can…

This study tests a combination of two drugs, monalizumab and durvalumab, plus chemotherapy for people with small cell lung cancer. The goal is to see if this mix can keep the cancer from growing longer than standard treatment. About 84 adults with either extensive or limited stag…

This study tests a new drug called ZG006 combined with standard immunotherapy (with or without chemotherapy) as a first treatment for people with extensive-stage small cell lung cancer. About 100 adults aged 18-75 with good performance status are being recruited. The main goals a…

This early-stage study tests a new drug called DXC014 in about 150 people with advanced solid tumors, including small cell lung cancer, melanoma, and prostate cancer. The main goals are to check safety, find the right dose, and see if the drug shows any signs of shrinking tumors.…

This early-stage trial tests an experimental oral drug called NKT3964 in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by degrading a protein (CDK2) that helps cancer cells grow. The study has two parts: first, find…

This study tests two experimental drugs, MK-6070 and ifinatamab deruxtecan (I-DXd), alone or together, in people with advanced small cell lung cancer that stopped responding to standard treatment. The goal is to see if these combinations can shrink tumors and are safe. About 262 …

This early-stage trial tests a new drug called KIVU-107 in 76 adults with advanced solid tumors that have not responded to standard treatments. KIVU-107 is an antibody-drug conjugate designed to target and kill cancer cells. The main goal is to find a safe dose and check for side…

This phase 1 trial tests a personalized, accelerated radiation therapy for locally advanced lung cancer. The radiation dose is tailored to each patient's tumor size and location, aiming to deliver a higher dose in fewer sessions. The study will enroll 45 adults with non-small cel…

This early-phase trial is testing an investigational drug called SYS6043 in adults with advanced or metastatic solid tumors that have spread or no longer respond to standard treatments. The study aims to find a safe dose and watch for side effects, while also looking for early si…

This Phase 2 trial tests whether adding trilaciclib to the chemotherapy drug lurbinectedin can reduce severe neutropenia (a dangerous drop in white blood cells) in people with small cell lung cancer that has spread. About 30 participants will receive both drugs intravenously. The…

This phase 2 trial tests fingolimod, a drug already used for multiple sclerosis, in 38 adults with advanced non-small cell or small cell lung cancer that worsened after chemo-immunotherapy. Participants take a 0.5 mg pill daily. The study first checks safety, then looks at whethe…

This Phase 3 trial is testing whether AK112 (Ivonescimab), a bispecific antibody that targets both PD-1 and VEGF, can help prevent cancer progression in people with limited-stage small-cell lung cancer who have completed chemoradiation. About 560 participants will receive either …

This early-stage study tests the safety of combining the drug talazoparib with low-dose chest radiation in people with extensive-stage small cell lung cancer that has not worsened after initial chemotherapy. About 24 participants will receive talazoparib pills daily during radiat…

This study is for people newly diagnosed with extensive-stage small cell lung cancer that has spread. Researchers want to see if adding a precise, high-dose radiation treatment (ablative radiation) to the standard combination of durvalumab (an immunotherapy) and chemotherapy (car…

This study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…

This early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…

This study tests a new combination of drugs (chidamide, a PD-L1 inhibitor, carboplatin, and etoposide) as the first treatment for people with extensive-stage small-cell lung cancer, a fast-growing cancer that has spread. About 36 participants will receive the combination for 4 cy…

This study tests a new drug called TCC1727 combined with other medicines (benmelstobart, olaparib, or topotecan) in people with advanced solid tumors, including lung, stomach, endometrial cancer, and melanoma. The goal is to find the safest dose and see if the combination helps s…

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 470 adults will tak…

This program provides early access to the investigational drug ABBV-706 for people with small cell lung cancer who have no other treatment options and cannot join a clinical trial. A doctor must decide if the potential benefit outweighs the risks. The drug is given by intravenous…

This study tests a new drug called IDE849, alone or with other drugs, in people with cancers that have a protein called DLL3, including small cell lung cancer. The trial has two phases and aims to see if the drug is safe and shrinks tumors. About 208 participants who have already…

This early-phase trial tests whether adding acetazolamide (a drug used for altitude sickness) to standard chemoradiation or radioimmunotherapy can help treat small cell lung cancer. About 27 adults with either localized or extensive small cell lung cancer will receive the combina…

This study tests two experimental drugs, ZG006 and ZG005, given together by IV in people with advanced small cell lung cancer or neuroendocrine carcinoma. The trial aims to see if the combination is safe and can shrink tumors. About 350 adults aged 18 to 70 are being recruited at…

This study tests an experimental drug called ZG006 in people with small cell lung cancer or neuroendocrine carcinoma who have run out of standard treatments or cannot tolerate them. The main goals are to find a safe dose and check for side effects. About 54 adults aged 18 to 75 w…

This Phase 3 trial compares a new drug called ZG006 with standard chemotherapy in 420 people whose small cell lung cancer has returned. The main goal is to see if ZG006 helps patients live longer. Participants will receive either ZG006 or one of several chemo options chosen by th…

This study tests whether adding a new drug called cirtuvivint to standard chemotherapy can help people with small cell lung cancer that has come back after initial treatment. About 42 adults whose cancer has progressed after at least one prior therapy will receive the combination…

This early-phase trial is testing a new drug called ST-001 in people with small cell lung cancer that has returned or not responded to standard treatments. The main goal is to find the safest dose and check for side effects. About 44 participants will receive the drug through an …

This phase 2 trial is testing a drug called onvansertib in about 37 people with small cell lung cancer that has come back or hasn't responded to chemotherapy. Onvansertib works by blocking a protein that cancer cells need to grow and repair themselves. The main goal is to see if …

This study tests an experimental drug called GV20-0251 in adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink tumors or slow their growth. About 350 participants with various cancers, including lung, mel…

This study tests a new drug called MB0151 in adults with advanced solid tumors, including certain lung, breast, and neuroendocrine cancers. The goal is to check the drug's safety and see if it can shrink or control tumors. About 156 participants will receive the drug intravenousl…

This study tests a new biologic drug called ZG006 in people with advanced small cell lung cancer or neuroendocrine carcinoma. The trial has two parts: first, finding a safe dose (Phase 1), then testing how well it shrinks tumors (Phase 2). About 265 participants will receive ZG00…

This early-stage trial is testing a new oral drug called NMS-03305293, combined with the chemotherapy temozolomide, in 10 people with relapsed small cell lung cancer. The main goal is to check safety and tolerability, while also looking for signs that the tumors shrink. All parti…

This early-stage study tests a new drug called DAY301 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a powerful toxin directly to cancer cells while sparing healthy ones. The study aims to find the safest dose …

This study tests two experimental drugs, BL-B01D1 and SI-B003, alone or together in people with extensive-stage small cell lung cancer that has spread. The goal is to see if these treatments can shrink tumors or slow the disease. About 100 adults aged 18 to 75 with good performan…

This early-stage trial tests a new drug called NN3201 in people with advanced cancers that have a specific marker called c-Kit. The drug is designed to deliver a chemotherapy agent directly to cancer cells, potentially killing them while sparing healthy tissue. The study will enr…

This early-phase study tests a new drug called BL-M14D1 in 22 adults with advanced small cell lung cancer, neuroendocrine tumors, or other solid cancers that have not responded to standard treatments. The drug is given by IV every 3 weeks. The main goals are to check safety, find…

This early-stage trial tests an experimental oral drug called CID-078 in 220 adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, finding a safe dose, and then checking if the drug shrinks tumors. It is a firs…

This early-stage trial is testing an experimental drug called LB1410, a bispecific antibody designed to block two immune checkpoints (PD-1 and TIM-3) and help the immune system fight cancer. It involves 100 adults with advanced solid tumors or lymphoma who have exhausted standard…

This study tests a new radioactive tracer called 89Zr-DFO-SC16.56 that attaches to a protein called DLL3 found on small cell lung cancer cells. The goal is to see if PET scans using this tracer can safely and accurately show where the cancer is in the body. About 53 adults with s…

This study is testing a new radioactive probe called PFD3, used with a PET/CT scan, to see if it can better find and assess small cell lung cancer (SCLC) by targeting a protein called DLL3 found on cancer cells. About 30 adults with SCLC will receive both a standard FDG scan and …

This study is testing a new imaging agent called 18F-T2, which is designed to highlight tumors that produce a protein called CAIX. About 200 adults with various cancers (like kidney, lung, or breast cancer) will receive an injection of 18F-T2 and then undergo a PET/CT scan. The g…

This study is testing whether measuring telomeres (parts of your DNA) in a blood sample can help doctors diagnose lung cancer. Researchers will collect blood from 1,200 people, including those with lung cancer and healthy volunteers, to build a predictive algorithm. The goal is t…

This early-stage study is testing a new imaging agent called 68Ga-FL-031 to see if it can better detect and stage certain cancers, including small cell lung, breast, and nasopharyngeal tumors. Ten adults with suspected or confirmed cancer will receive both the new PET scan and a …

This study is testing whether a very powerful 7 Tesla MRI can detect tiny brain metastases earlier than standard 1.5 or 3 Tesla MRIs in people with small-cell lung cancer who choose not to have preventive brain radiation. Twenty participants will get a 7T brain scan followed by u…

This study tests a Hospital-at-Home program for people with small cell lung cancer receiving tarlatamab. The goal is to see if monitoring patients at home using telemedicine is as safe and effective as keeping them in the hospital after treatment. About 70 adults will take part, …

This study tests a brief program called Pathways, designed to help people with advanced lung cancer set personal goals and improve their mental health and quality of life during treatment. About 234 participants will be randomly assigned to receive either the Pathways program or …

This study tests a 6-week mindfulness-based program for lung cancer patients struggling with breathlessness, cough, and fatigue. The program combines mindful breathing, relaxation, cough control, acupressure, and light exercise. Researchers will check if it's practical and liked …

This phase 3 trial tests whether a daily nutritional drink (Oral Impact®) can reduce severe throat and esophagus inflammation caused by chest radiation in lung cancer patients. About 121 adults with lung cancer who need radiation will drink two bottles a day during and for three …

This study tests whether a special imaging method (4DCT) can help doctors avoid giving too much radiation to healthy, working parts of the lung during radiotherapy for lung cancer. About 100 adults with lung cancer will receive standard radiation, but their treatment plan will be…

This study tests a program called CARES that provides nurse navigators and counselors to rural cancer patients. The goal is to see if this support helps patients start and finish treatment more quickly and improves their quality of care. About 320 adults with solid tumors like lu…

This study collects tissue samples and health information from 2000 adults with certain lung and thymic cancers. Researchers aim to better understand these diseases, which could lead to new diagnostic tools and treatments. Participants provide blood, tumor samples, and imaging da…

This study is observing 200 people with extensive stage small cell lung cancer to learn more about the genetic makeup of their tumors. Researchers will analyze tumor tissue and blood samples to see if certain genetic patterns are linked to how well treatments work. The goal is to…

This pilot study will test whether lung cancer patients can use an Apple Watch, a home pulse oximeter, and a smartphone to collect health data during proton beam radiotherapy. About 40 participants will wear the devices from the start of treatment until two weeks after it ends. T…

This study tests whether a newer, MRI-guided radiation method (MRgART) is gentler on the heart than standard radiation (LINAC) for people with lung, esophageal, or other chest cancers. About 60 adults will receive radiation and have their heart function checked via MRI and blood …

This study is for people with solid tumors that have spread to the brain. Researchers want to collect medical information and samples (like blood and spinal fluid) to better understand why and how brain metastases happen. The goal is to find new ways to treat or prevent them in t…

This study is building a large database of blood samples, tumor samples, and scans from 4,000 people with lung cancer. Researchers will follow participants for up to 10 years to collect information that can help future studies. The goal is to better understand lung cancer and imp…

This study is a registry that will collect information from about 3,750 adults with lung cancer across 21 hospitals in Algeria. Researchers will track patients' health, treatments, and outcomes during routine care. The goal is to better understand lung cancer in Algeria and help …

This study collects tumor samples from 50 lung cancer patients whose disease has worsened while on immunotherapy. The goal is to analyze the tissue for clues about why the treatment stopped working. No new drug is being tested; instead, researchers hope to better understand resis…